Regeneron Pharmaceuticals Inc
(LTS:0R2M)
$
827.21
-6.645 (-0.8%)
Market Cap: 91.15 Bil
Enterprise Value: 84.05 Bil
PE Ratio: 20.53
PB Ratio: 3.11
GF Score: 93/100 Regeneron Pharmaceuticals Inc at Jefferies London Healthcare Conference Transcript
Nov 16, 2022 / 03:15PM GMT
Release Date Price:
$735.82
(+1.18%)
Akash Tewari
Jefferies LLC, Research Division - Equity Analyst
All right. Well, good afternoon. Day 2 of the London Healthcare Conference. My name is Akash Tewari. I'm one of the therapeutic analyst here. I hope you guys are all enjoying yourself. I'll tell you, it's wonderful to see everyone back, it really is. So today, I have the pleasure of hosting Regeneron. Joining us today, we have Robert Landry, CFO; and then Ryan Crowe, Head of IR. Before we get into some of the specific questions we had, maybe Robert and Ryan, do you want to open up with some introductory remarks, and we can take it from there.
Ryan Crowe
Regeneron Pharmaceuticals, Inc. - VP of IR
Sure. Absolutely.
Akash Tewari
Jefferies LLC, Research Division - Equity Analyst
Do you mind closing the door, please?
Ryan Crowe
Regeneron Pharmaceuticals, Inc. - VP of IR
Yes. I'll just start here with some -- and thank you for having us, Akash. Great to be in London meeting with everybody and certainly a very
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot